680 related articles for article (PubMed ID: 34027753)
1. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
[TBL] [Abstract][Full Text] [Related]
2. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
[TBL] [Abstract][Full Text] [Related]
3. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
[TBL] [Abstract][Full Text] [Related]
5. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
[TBL] [Abstract][Full Text] [Related]
6. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
[TBL] [Abstract][Full Text] [Related]
7. Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.
Penton H; Jayade S; Selveindran S; Heisen M; Piketty C; Ulianov L; Jabbar-Lopez ZK; Silverberg JI; Puelles J
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2549-2571. PubMed ID: 37747670
[TBL] [Abstract][Full Text] [Related]
8. Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany.
Weisshaar E; Bentz P; Apfelbacher C; Haufe E; Heinrich L; Heratizadeh A; Abraham S; Harder I; Kleinheinz A; Wollenberg A; Schäkel K; Wiemers F; Ertner J; Augustin M; Wildberger J; Von Kiedrowski R; Worm M; Zink A; Effendy I; Asmussen A; Pawlak M; Sticherling M; Hilgers M; Handrick C; Quist S; Schwarz B; Bell M; Staubach-Renz P; Hong-Weldemann SH; Homey B; Brücher JJ; Weidinger S; Werfel T; Schmitt J;
Acta Derm Venereol; 2023 Jan; 103():adv00854. PubMed ID: 36688701
[TBL] [Abstract][Full Text] [Related]
9. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis.
Lee HH; Patel KR; Rastogi S; Singam V; Vakharia PP; Chopra R; Silverberg JI
J Am Acad Dermatol; 2020 Jan; 82(1):62-71. PubMed ID: 31202874
[TBL] [Abstract][Full Text] [Related]
10. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
[TBL] [Abstract][Full Text] [Related]
11. Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.
Schwartzman G; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY; Silverberg JI
J Am Acad Dermatol; 2021 Sep; 85(3):636-644. PubMed ID: 33484762
[TBL] [Abstract][Full Text] [Related]
12. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
[TBL] [Abstract][Full Text] [Related]
13. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
[TBL] [Abstract][Full Text] [Related]
14. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
Leshem YA; Chalmers JR; Apfelbacher C; Katoh N; Gerbens LAA; Schmitt J; Spuls PI; Thomas KS; Howells L; Williams HC; Simpson EL;
JAMA Dermatol; 2022 Dec; 158(12):1429-1435. PubMed ID: 36223090
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
[TBL] [Abstract][Full Text] [Related]
16. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Guttman-Yassky E; Bar J; Rothenberg-Lausell C; Eichenfield L; Grada A; Abuabara K; Chapman M; Calimlim B; Wegzyn C; Gamelli A; Krueger W; Munoz B; Knapp K; Faller R; Crawford J; Silverberg J
J Drugs Dermatol; 2023 Apr; 22(4):344-354. PubMed ID: 37026893
[TBL] [Abstract][Full Text] [Related]
17. Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patients.
Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Sacotte R; Patel KR; Singam V; Immaneni S; Kantor R; Hsu DY; Silverberg JI
Ann Allergy Asthma Immunol; 2020 Mar; 124(3):261-266. PubMed ID: 31830585
[TBL] [Abstract][Full Text] [Related]
18. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis.
Gooderham MJ; Bissonnette R; Grewal P; Lansang P; Papp KA; Hong CH
J Cutan Med Surg; 2018; 22(1_suppl):10S-16S. PubMed ID: 30439297
[TBL] [Abstract][Full Text] [Related]
19. Validation of patient-reported global severity of atopic dermatitis in adults.
Vakharia PP; Chopra R; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
Allergy; 2018 Feb; 73(2):451-458. PubMed ID: 28905999
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
